Hyperfine (HYPR) Hisse Özeti

Bir sağlık teknolojisi şirketi olan Hyperfine, Inc. manyetik rezonans görüntüleme (MRI) ürünlerinin üretimi, tedariki, servisi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay

HYPR temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 40.8% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 4.1% oranında arttı

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

HYPR Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

Hyperfine

AnalystConsensusTarget

Based on Analyst Price Targets

HYPR: International Approvals And Expanded Use Will Drive Upside Momentum

Key Takeaways Valuation relies on aggressive assumptions of rapid adoption, strong pricing power, and seamless international expansion amid demographic and healthcare trends. Sustained growth expectations are vulnerable to delays, competitive innovation, regulatory headwinds, or setbacks in technological integration and payer acceptance.

View narrative

US$1.65

35.2% değerinin altında

46.55%

Revenue growth p.a.

Hyperfine

AnalystHighTarget

Community Contributor

Global Aging And Telemedicine Will Drive Portable MRI Adoption

Key Takeaways Rapid clinical adoption, global expansion, and unique use-cases position Swoop for outsized revenue growth and transformative market share gains over traditional MRI. Strong network effects, recurring high-margin revenue, and scalable operations suggest substantial improvement in operating margins and long-term profitability.

View narrative

US$2

46.5% değerinin altında

31.02%

Revenue growth p.a.

Hyperfine

AnalystLowTarget

Community Contributor

Supply Disruptions And Delayed Adoption Will Undermine Long-Term Outlook

Key Takeaways Weak differentiation, high costs, and market resistance threaten sustained adoption, limiting pricing power, recurring revenue, and delaying profitability. Supply chain risks, regulatory challenges, and competition from alternative technologies could further constrain market size, margin recovery, and overall earnings growth.

View narrative

US$1.3

17.7% değerinin altında

49.09%

Revenue growth p.a.

View Stock Community

Hyperfine, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Hyperfine
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.07
52 Haftanın En Yüksek Seviyesi	US$2.22
52 Haftanın En Düşük Seviyesi	US$0.53
Beta	1.09
1 Aylık Değişim	2.88%
3 Aylık Değişim	-29.14%
1 Yıllık Değişim	20.22%
3 Yıllık Değişim	27.38%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-89.31%

Son Haberler & Güncellemeler

Recent updates

Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump

Oct 07

Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher

Jul 23

Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely

May 16

2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption

Apr 09 Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.

What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash

Mar 22

Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump

Feb 05

Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results

Nov 15

Hyperfine appoints Maria Sainz as President, CEO

Oct 06

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Aug 10

Hyperfine stock plunges 14% as CEO Dave Scott steps down

Jun 29

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Apr 04

Hyperfine: MR Imaging In A Swoop

Mar 09

Hissedar Getirileri

	HYPR	US Medical Equipment	US Pazar
7D	-2.7%	0.3%	1.3%
1Y	20.2%	3.7%	15.8%

Getiri vs. Endüstri: HYPR geçen yıl % 3.7 oranında getiri sağlayan US Medical Equipment sektörünü aştı.

Getiri vs Piyasa: HYPR geçen yıl % 15.8 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is HYPR's price volatile compared to industry and market?
HYPR volatility
HYPR Average Weekly Movement	16.9%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	6.5%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: HYPR hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: HYPR 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	111	Maria Sainz	hyperfine.io

Bir sağlık teknolojisi şirketi olan Hyperfine, Inc. manyetik rezonans görüntüleme (MRI) ürünlerinin üretimi, tedariki, servisi ve ticarileştirilmesi ile ilgilenmektedir. Swoop Taşınabilir MR Görüntüleme Sistemi, geleneksel MR tarayıcılarından daha düşük bir manyetik alan gücünde görüntüler üretir. Şirket ayrıca destek ve teknik yardım hizmetlerinin yanı sıra bir bulut görüntü arşivleme ve iletişim sistemi olan Hyperfine Image Viewer'ı da sunmaktadır.

Hyperfine, Inc. Temel Bilgiler Özeti

Hyperfine'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HYPR temel i̇stati̇sti̇kler
Piyasa değeri	US$103.97m
Kazançlar(TTM)	-US$40.05m
Gelir(TTM)	US$10.59m

9.8x

P/S Oranı

-2.6x

F/K Oranı

HYPR aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HYPR gelir tablosu (TTM)
Gelir	US$10.59m
Gelir Maliyeti	US$5.71m
Brüt Kâr	US$4.89m
Diğer Giderler	US$44.94m
Kazançlar	-US$40.05m

Son Raporlanan Kazançlar

Sep 30, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.41
Brüt Marj	46.12%
Net Kâr Marjı	-378.17%
Borç/Özkaynak Oranı	0%

HYPR uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/12/26 23:02
Gün Sonu Hisse Fiyatı	2025/12/24 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Hyperfine, Inc. 3 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yuan Zhi	B. Riley Securities, Inc.
Vijay Kumar	Evercore ISI
Frank Takkinen	Lake Street Capital Markets, LLC

Hyperfine (HYPR) Hisse Özeti

Ödüller

Risk Analizi

HYPR: International Approvals And Expanded Use Will Drive Upside Momentum

Global Aging And Telemedicine Will Drive Portable MRI Adoption

Supply Disruptions And Delayed Adoption Will Undermine Long-Term Outlook

Hyperfine, Inc. Rakipler

Pulmonx

Neuronetics

Zomedica

Kewaunee Scientific

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Hyperfine, Inc. Announces Regulatory Approval of the Swoop®? System in India

Hyperfine Announces FDA Clearance of the First Optive AI Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop System

Hyperfine, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025

Recent updates

Hyperfine, Inc. Announces Regulatory Approval of the Swoop®? System in India

Hyperfine Announces FDA Clearance of the First Optive AI Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop System

Hyperfine, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025

Hyperfine, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Hyperfine, Inc. Announces Plans for Clinical Use Expansion into the Operating Room Environment

Hyperfine, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.

Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump

Hyperfine, Inc. Launches PULSE Platform to Accelerate Adoption and Innovation of AI-Powered Portable MRI

Hyperfine Receives UKCA Approval for Optive AI Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2025

Hyperfine, Inc. Achieves Clinical Milestone Ahead of Plan with 100Th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System

Hyperfine Announces First Patients Enrolled in Prime Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments

Hyperfine, Inc. Announces Promising Early Results from the CARE PMR

Hyperfine Swoop AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care

Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher

Hyperfine, Inc. Begins Commercial Launch of Optive AI™? Software, Bringing Substantially Improved Image Quality to the Installed Base of Swoop®? Systems

Hyperfine Announces the First Commercial Sales of the Next-Generation Swoop®? System Powered by Optive AI™ Software

Hyperfine, Inc. Announces Appointments of Rob Fasciano as Chief Regulatory and Quality Officer

Hyperfine, Inc. Announces FDA Clearance of New Next-Generation Swoop System Powered by Optive AI Software, Delivering Transformative Leap in Image Quality

Hyperfine, Inc. Announces FDA Clearance of Optive AI™? Software, Introducing the Most Substantial Image Quality Improve Ever for the Swoop®? System

Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely

Hyperfine, Inc. Provides Revenue Guidance for the First Half of 2025

Hyperfine Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Hyperfine, Inc. to Report Q1, 2025 Results on May 13, 2025

Hyperfine, Inc. Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption

Hyperfine, Inc., Annual General Meeting, May 19, 2025

What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash

Hyperfine, Inc. Provides Earnings Guidance for the First Half and Full Year 2025

Hyperfine, Inc. to Report Q4, 2024 Results on Mar 17, 2025

Hyperfine, Inc. Provides Earnings Guidance for the Fiscal Year Ended December 31, 2024

Hyperfine, Inc. has filed a Follow-on Equity Offering.

Hyperfine, Inc. Reports on Growing Evidence for the Use of Swoop® System Images in Stroke Diagnosis Presented at the 2025 International Stroke Conference

Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump

Hyperfine, Inc. Announces Extensive Clinical Study Coverage At Radiological Society of North America 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop System Across Different Sites of Care

Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results

Hyperfine, Inc. Updates Revenue Guidance for the Year 2024

Hyperfine, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients

Hyperfine, Inc. Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-In-Class Ultra-Low-Field Brain Images

Hyperfine, Inc. Highlights Positive Results from Multi-Site Observational Study on Swoop® System for Stroke Assessment

Hyperfine, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine, Inc. Provides Earnings Guidance for the Year 2024

Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024

Hyperfine, Inc., Annual General Meeting, Jun 11, 2024

Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System

Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Hyperfine, Inc. Announces Executive Changes

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System

Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up

Hyperfine, Inc. Announces Chief Financial Officer Changes

Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022